For decades, life sciences companies have had a relatively familiar idea of what a senior executive should look like.
A scientist with decades of industry experience. A commercial leader who has worked at several major pharmaceutical companies. A regulatory executive with a long history of approvals. A CFO who has navigated multiple financings or public offerings.
These backgrounds remain valuable. But the industry is changing faster than traditional executive career paths.
Artificial intelligence, advanced analytics, precision medicine, decentralized clinical models, new manufacturing technologies, and increasingly complex healthcare economics are creating problems that previous generations of executives were never trained to solve.
This raises a question that boards should be asking more often: Are we still looking for the leaders the industry needed ten years ago?
The old career map is becoming less reliable
Traditional executive hiring often works through recognizable patterns. Company A produces a successful executive. Company B recruits them. Eventually they move to Company C, bringing increasingly senior titles and a familiar collection of experiences.
There is nothing inherently wrong with this model. The problem arises when the industry itself changes faster than those career paths.
Some of the challenges facing today’s life sciences companies simply do not have decades of established experience behind them. AI-native drug discovery, data-driven clinical development, personalized therapies, and new commercial models are developing too quickly for a large pool of executives to have already mastered them.
That means companies may need to evaluate leadership potential differently. Instead of asking only, “Who has done this before?” they may need to ask, “Who has demonstrated the ability to learn, adapt, and lead through something genuinely new?”
Transferable experience matters more than perfect experience
This does not mean hiring people without relevant experience. It means understanding that relevance can take different forms.
A leader who has managed a major digital transformation in another highly regulated industry may bring valuable lessons to a pharmaceutical organization undergoing technological change. An executive who has built a data-driven business model outside traditional healthcare may see opportunities that an industry insider takes for granted.
The key is identifying which experiences are genuinely transferable.
- Have they operated in a regulated environment?
- Have they managed scientific or technical complexity?
- Have they led through uncertainty?
- Have they built credibility with highly specialized teams?
- Have they made consequential decisions in ambiguous environments?
These questions can reveal leadership capability that a conventional résumé screen might miss. Credentials and status can be useful signals, but they do not necessarily forecast how someone would perform in a particular environment.
The danger is overcorrecting
There is, however, a risk in becoming too enthusiastic about “non-traditional” talent. Novelty is different from capability.
A board should not hire someone from another industry simply because their background looks different. Nor should a company assume that a technology executive automatically understands the scientific, regulatory, and ethical complexity of life sciences.
The goal is not to abandon industry experience. It is to broaden the definition of relevant experience. The strongest leadership teams may increasingly combine deep domain expertise with perspectives from outside traditional industry boundaries. That combination can be particularly powerful when the organization is entering unfamiliar territory.
Different perspectives become more valuable as complexity increases
As life sciences organizations become more interconnected with technology, data, healthcare systems, manufacturing, and global markets, leadership problems increasingly cross functional boundaries.
- A scientific decision can become a commercial decision.
- A technology decision can become a regulatory decision.
- A manufacturing issue can become an investor-confidence issue.
- A data governance question can become a patient-trust issue.
Leaders who have spent their entire careers inside one functional silo may find these intersections more challenging than executives accustomed to navigating across disciplines.
This is one reason leadership teams themselves are becoming more important than individual executive pedigrees.
A company does not necessarily need one person who knows everything. It needs a group of leaders whose capabilities complement one another and who can work effectively across boundaries.
The future belongs to adaptable leaders
The most valuable leadership trait in a rapidly changing industry may ultimately be adaptability and not the vague kind that may appear in an executive résumé.
Real adaptability means being able to recognize when an established approach is no longer working, absorb unfamiliar information, change direction without losing confidence, and lead a team through uncertainty. That capability is difficult to assess from titles alone. It emerges through career choices, difficult situations, failures, transformations, and decisions where there was no obvious playbook.
For boards, this creates an important shift in how executive potential should be assessed. The strongest candidate may not have the most obvious career trajectory. They may be the person whose career demonstrates a repeated ability to enter complex situations, understand them quickly, and create meaningful change.
The executive market is becoming more interesting
This shift is good news for companies willing to look beyond conventional talent pools. It creates access to leaders who might previously have been overlooked because they did not follow a traditional pharmaceutical career path. It also creates a more sophisticated challenge for executive search: identifying which differences matter and which are simply distractions. That requires context. It requires understanding both the organization and the candidate deeply enough to distinguish genuine transferable capability from an attractive but irrelevant résumé.
The companies that get this right may discover that their next transformative leader is not necessarily in the place they have traditionally looked.
Leadership should reflect the future, not just validate the past
There is comfort in hiring someone whose career resembles those who succeeded before them. But the future is not required to resemble the past.
Life sciences is entering an era where scientific innovation, technology, data, regulation, capital, and patient expectations are converging in ways that will create entirely new leadership challenges.
The companies prepared for that future will not abandon experience. They will become much more thoughtful about what experience truly matters. The best leader for tomorrow may not have the perfect résumé. They may have something more valuable: the judgment, curiosity, resilience, and adaptability to succeed when the old résumé stops being a reliable guide.
GeneCoda® works with life sciences boards and founders to identify leadership capability that aligns with where an organization is going rather than where it has been. If you’re considering an executive hire and the traditional candidate profile no longer feels sufficient, contact us to discuss a broader, more strategic approach to the search.
